← Back to Home

Pimicotinib Receives FDA Approval, Adding a Treatment Option for Patients With Tenosynovial Giant Cell Tumor Who Face High Surgical Risk

For some patients, removing a tumor may also mean sacrificing joint function. The newly approved oral drug increased tumor response rates and improved pain and mobility in a randomized trial, but risks including hepatotoxicity must still be weighed in treatment decisions.

By SURL BioNews

When removing a tumor could make a joint harder to move, treatment presents a dilemma. On November 10, 2026, the U.S. Food and Drug Administration (FDA) approved the oral drug pimicotinib, marketed as Pimjetmi, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for whom surgical removal could worsen functional limitations or cause serious complications. The approval adds a drug treatment option for these patients.

TGCT is a rare, locally aggressive tumor that primarily affects joints, tendon sheaths, and bursae, and can cause pain, swelling, and stiffness. According to developer Abbisko Therapeutics, tumor cells overexpress colony-stimulating factor 1 (CSF-1), causing inflammatory cells bearing its receptor, CSF-1R, to accumulate in the tumor. Pimicotinib is a small-molecule inhibitor that targets CSF-1R.

MANEUVER, which supported the approval, is an international, double-blind, placebo-controlled trial in which participants were randomized in a two-to-one ratio to receive pimicotinib or placebo. At week 25, independent blinded imaging review found an overall response rate of 56% in the drug group and 3.2% in the placebo group. This measure indicates tumor shrinkage meeting predefined criteria and cannot be interpreted as a cure rate.

Beyond imaging, the trial also assessed whether patients could use the affected joint more comfortably. Both the FDA and The ASCO Post reported that the pimicotinib group showed significantly greater improvements than the placebo group on prespecified measures including joint range of motion, pain, and physical function. This extends the significance of the treatment's benefits from tumor size to daily life, although these results still come from patients enrolled under specific eligibility criteria.

How long the benefits last is another key question. Citing longer-term follow-up, The ASCO Post reported that the median duration of response had not yet been reached; the FDA stated that, among responders, 77% had responses lasting at least 12 months. The denominator for this percentage is patients who responded, rather than everyone who received treatment; a median that has not yet been reached also does not mean the benefits can continue indefinitely. Because the control group received placebo, the trial also cannot directly determine how the drug compares with other treatments.

Drug risks also influence treatment decisions. Common adverse reactions listed in the FDA announcement include itching, rash, edema, and fatigue; the prescribing information also warns of hepatotoxicity, embryo-fetal toxicity, and elevated serum creatinine without accompanying impairment of kidney function. The approved recommended dose is 50 milligrams orally once daily, with or without food.

Commercial plans are also moving forward following U.S. approval. According to an Abbisko announcement, the company developed pimicotinib and licensed global commercialization rights to Germany's Merck KGaA; the first commercial sale in the United States will trigger an additional milestone payment, and Abbisko is also eligible to receive royalties at a double-digit percentage of global net sales. The company said the drug had previously been approved in China in December 2025, in Canada in June 2026, and in Switzerland in October of the same year. However, obtaining marketing approval and whether patients can actually afford and access treatment remain separate issues.

References

  1. U.S. Food and Drug Administration
  2. Abbisko Therapeutics via PR Newswire
  3. The ASCO Post